Published in
American Association for the Advancement of Science, Science Translational Medicine, 622(13), 2021
DOI: 10.1126/scitranslmed.abf4530
Links
Tools
Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics”
Journal article published in 2021 by
Jonas Bovijn 
,
Kristi Krebs ,
Chia-Yen Chen ,
Ruth Boxall ,
Jenny C. Censin ,
Teresa Ferreira ,
Sara L. Pulit ,
Craig A. Glastonbury ,
Samantha Laber,
Iona Y. Millwood,
Kuang Lin,
Liming Li ,
Zhengming Chen,
Lili Milani ,
George Davey Smith
and other authors.
,
Kristi Krebs ,
Chia-Yen Chen ,
Ruth Boxall ,
Jenny C. Censin ,
Teresa Ferreira ,
Sara L. Pulit ,
Craig A. Glastonbury ,
Samantha Laber,
Iona Y. Millwood,
Kuang Lin,
Liming Li ,
Zhengming Chen,
Lili Milani ,
George Davey Smith
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.